Patents Assigned to The University of Edinburgh
-
Patent number: 12102069Abstract: The present invention provides livestock animals and methods to create recipient animals for spermatogonial stem cell transplantation through modulation of the NANOS gene. In one embodiment genome editing issued to create animals with insertions or deletions (indels) that inactivate or otherwise modulate NANOS gene activity so that resulting males lack functional germ cells yet retain functional somatic cells, and females are fertile. These males can then be transplanted with donor spermatogonial stem cells and used for breeding.Type: GrantFiled: March 20, 2020Date of Patent: October 1, 2024Assignees: Washington State University, University of Maryland, The University Court of The University of EdinburghInventors: Jon Michael Oatley, Christopher Bruce Alexander Whitelaw, Simon Geoffrey Lillico, Bhanu Prakash Telugu
-
Patent number: 11099197Abstract: A method of detecting the presence of alpha-synuclein aggregation in a biological sample is provided whereby a biological sample is mixed with a reaction sample comprising a population of beads, a fluorophore adapted to bind to protein aggregates and to increase fluorescence when bound to protein aggregates, and alpha-synuclein or a fragment or variant thereof to form a reaction mixture, the reaction mixture is illuminated and at the same time incubated with intermittent agitation cycles, wherein a significant increase in the fluorescence of the reaction mixture during incubation is indicative of the presence of aggregates of alpha-synuclein in the biological sample. Method of diagnosing alpha-synucleinopathies such as Parkinson's disease or Dementia with Lewy Bodies.Type: GrantFiled: July 6, 2017Date of Patent: August 24, 2021Assignee: The University Court Of The University of EdinburghInventors: Alison Green, Graham Fairfoul
-
Patent number: 10611756Abstract: The present invention relates to methods and/or uses for treating pancreatitis, kidney diseases and other various disorders as described herein, for conditions or disorders mediated by KMO inhibitors, which comprises administering 6-chlorobenzoxazine compounds of Formula (I): or pharmaceutically acceptable salts and/or corresponding pharmaceutical compositions thereof.Type: GrantFiled: February 8, 2019Date of Patent: April 7, 2020Assignee: The University Court of The University of EdinburghInventors: Anne Marie Jeanne Bouillot, Alexis Denis, John Liddle, Olivier Mirguet, Ann Louise Walker
-
Patent number: 10208166Abstract: A polyphosphonate, a lens including the polyphosphonate, a camera module including the polyphosphonate lens, and a method of producing the lens are provided. The polyphosphonate includes a constitutional repeating unit comprising a phosphate ester group and an aromatic ring, and the phosphate ester group is directly bonded to the aromatic ring in the constitutional repeating unit.Type: GrantFiled: March 18, 2016Date of Patent: February 19, 2019Assignees: Samsung Electro-Mechanics Co., Ltd., The University Court of The University of EdinburghInventors: Hoe-Chul Jung, Michael Patrick Shaver, Emily Kate Macdonald
-
Publication number: 20180112193Abstract: The present invention relates to compositions of matter and methods of using the same in enhancing regeneration or restoring function of an injured liver. The compositions of matter are useful in the treatment of hepatic disorders, for example, in the prevention and/or treatment of acute or chronic liver disease or as a supportive therapy to improve the outcomes following liver resection or liver transplantation.Type: ApplicationFiled: September 8, 2017Publication date: April 26, 2018Applicant: University Court Of The University Of EdinburghInventors: Stuart Forbes, David Hume, Ben Stutchfield, Deborah Gow, Graeme Bainbridge, Theodore Oliphant, Thomas L. Wilson
-
Patent number: 9725697Abstract: The present invention provides an isolated population of chondrocyte precursor cells wherein 1% or less of the cells express Oct4, Nanog and/or TRA-1-60, 7% or less of the cells express no collagen II, collagen X, CD105 or Stro-1 and 85% or more of the cells express CBFA1, methods for preparing such cells and uses of chondrocyte cells derived from said precursor cells.Type: GrantFiled: May 11, 2015Date of Patent: August 8, 2017Assignee: The University Court of The University of EdinburghInventors: Brendon Stewart Noble, David Matthew Pier
-
Publication number: 20160289391Abstract: A polyphosphonate, a lens including the polyphosphonate, a camera module including the polyphosphonate lens, and a method of producing the lens are provided. The polyphosphonate includes a constitutional repeating unit comprising a phosphate ester group and an aromatic ring, and the phosphate ester group is directly bonded to the aromatic ring in the constitutional repeating unit.Type: ApplicationFiled: March 18, 2016Publication date: October 6, 2016Applicants: Samsung Electro-Mechanics Co., Ltd., The University Court of The University of EdinburghInventors: Hoe-Chul JUNG, Michael Patrick Shaver, Emily Kate Macdonald
-
Patent number: 9365564Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone, 3,3-disubstituted-(6-aza-bicyclo[3.1.1]hept-6-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone, and 4,4-disubstituted piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds of the following formula that, inter alia, inhibit 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1).Type: GrantFiled: March 10, 2011Date of Patent: June 14, 2016Assignee: The University Of EdinburghInventors: Scott Peter Webster, Jonathan Robert Seckl, Brian Robert Walker, Peter Ward, Thomas David Pallin, Hazel Joan Dyke, Trevor Robert Perrior
-
Patent number: 9309495Abstract: A homogenous, symmetrically dividing population of adherent neural stem cells is obtained from ES cells or foetal or adult brain isolates, using an activator of a signalling pathway downstream of a receptor of the EGF receptor family, optionally in combination with an activator of a signalling pathway downstream of an FGF receptor. The neural stem cell population is highly pure and retains the ability to differentiate into neurons after in excess of 100 passages.Type: GrantFiled: July 21, 2014Date of Patent: April 12, 2016Assignee: The University Court of The University of EdinburghInventors: Luciano Conti, Steven Michael Pollard, Austin Gerard Smith
-
Publication number: 20160053281Abstract: Compositions and method for treating a folate-resistant disease in a subject are disclosed. The methods involve administering to the subject an effective amount of a composition containing a formate. For example, the method can be used to reducing the risk of neural tube defects during pregnancy. The method can also be used to treat other conditions normally treatable by folate supplementation.Type: ApplicationFiled: March 24, 2014Publication date: February 25, 2016Applicant: The University Court Of The University Of EdinburghInventor: Peter Simmonds
-
Patent number: 9097654Abstract: The present invention relates to an electrode assembly having a laminate structure comprising: a first insulating capping layer; a first conducting layer capped by the first insulating capping layer and substantially sandwiched by at least the first insulating capping layer such as to leave exposed only an electrical contact lip of the first conducting layer; and an array of etched voids extending through at least the first insulating capping layer and the first conducting layer, wherein each void is partly bound by a surface of the first conducting layer which acts as an internal submicron electrode.Type: GrantFiled: November 30, 2009Date of Patent: August 4, 2015Assignee: Nanoflex Limited and The University Court Of The University of EdinburghInventors: Neville John Freeman, Andrew Raymond Mount, Anthony John Walton, Jonathan Gordon Terry
-
Patent number: 8642621Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11?-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11?-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.Type: GrantFiled: September 14, 2010Date of Patent: February 4, 2014Assignee: The University Of EdinburghInventors: Scott Peter Webster, Jonathan Robert Seckl, Brian Robert Walker, Peter Ward, Thomas David Pallin, Hazel Joan Dyke, Trevor Robert Perrior
-
Patent number: 8614209Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11?-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11?-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.Type: GrantFiled: September 13, 2012Date of Patent: December 24, 2013Assignee: The University of EdinburghInventors: Scott Peter Webster, Jonathan Robert Seckl, Brian Robert Walker, Peter Ward, Thomas David Pallin, Hazel Joan Dyke, Trevor Robert Perrior
-
Publication number: 20130333058Abstract: Pluripotent cells are derived and maintained in a self-renewing state in serum-free culture medium comprising a MEK inhibitor, a GSK3 inhibitor and an antagonist of an FGF receptor.Type: ApplicationFiled: April 5, 2013Publication date: December 12, 2013Applicant: The University Court of The University of EdinburghInventors: Qi-Long Ying, Austin Gerard Smith
-
Publication number: 20130172769Abstract: A method, apparatus, computer program, system and device for measuring oscillatory motion comprising: receiving a plurality of signals related to a plurality of measurements of a direction of a vector parameter (at-1, at); determining a predominant measured direction of the vector parameter (?t) based on the plurality of measurements of the direction of the vector parameter; determining an angle of rotation (?t) between: a measured direction of the vector parameter (at) of one of the plurality of measurements of the direction of the vector parameter, and the predominant measured direction of the vector parameter (?t).Type: ApplicationFiled: May 16, 2011Publication date: July 4, 2013Applicant: The University Court of The University of EdinburghInventors: Damal Arvind, Andrew Bates
-
Patent number: 8362008Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11?-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11?-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.Type: GrantFiled: December 11, 2008Date of Patent: January 29, 2013Assignee: The University Of EdinburghInventors: Scott Peter Webster, Jonathan Robert Seckl, Brian Robert Walker, Peter Ward, Thomas David Pallin, Hazel Joan Dyke, Trevor Robert Perrior
-
Patent number: 8299063Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11?-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11?-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.Type: GrantFiled: March 13, 2009Date of Patent: October 30, 2012Assignee: The University of EdinburghInventors: Scott Peter Webster, Jonathan Robert Seckl, Brian Robert Walker, Peter Ward, Thomas David Pallin, Hazel Joan Dyke, Trevor Robert Perrior
-
Publication number: 20120024571Abstract: The present invention relates to an electrode assembly having a laminate structure comprising: a first insulating capping layer; a first conducting layer capped by the first insulating capping layer and substantially sandwiched by at least the first insulating capping layer such as to leave exposed only an electrical contact lip of the first conducting layer; and an array of etched voids extending through at least the first insulating capping layer and the first conducting layer, wherein each void is partly bound by a surface of the first conducting layer which acts as an internal submicron electrode.Type: ApplicationFiled: November 30, 2009Publication date: February 2, 2012Applicants: The University Court of the The University of Edinburgh, Nanoflex LimitedInventors: Neville John Freeman, Andrew Raymond Mount, Anthony John Walton, Jonathan Gordon Terry
-
Patent number: 8045639Abstract: Provided is a multiple-input multiple-output (MIMO) data transmission method. A transmitter generates a transmission symbol by adding a parity symbol to a predetermined number of data symbols, generates a preprocessed symbol by multiplying the predetermined number of transmission symbols by a preprocessing matrix in units of blocks, selects a transmission antenna associated with a non-zero transmission symbol among preprocessed transmission symbols constituting the preprocessed symbol, and transmits the preprocessed symbol via the selected transmission antenna. A receiver receives a signal transmitted from the transmitter, estimates a preprocessed symbol and a transmission antenna index from the received signal, and restores the transmission symbols using the estimated preprocessed symbol and transmission antenna index.Type: GrantFiled: July 6, 2006Date of Patent: October 25, 2011Assignees: Samsung Electronics Co., Ltd., The University Court of The University of Edinburgh Old CollegeInventors: Yeon-Woo Lee, Sang-Boh Yun, Harald Haas, Raed Mesleh, Steve McLaughlin
-
Patent number: 7790706Abstract: The present invention relates to the modulation of glucocorticoid metabolism. In particular the invention relates to the modulation of the functional activity of the glucocorticoid receptor by 5? reduced metabolic breakdown products of glucocorticoids.Type: GrantFiled: December 14, 2004Date of Patent: September 7, 2010Assignee: The University of EdinburghInventors: Brian Robert Walker, Ruth Andrew